by Ghyslain Mombo-Ngoma, Jonathan Remppis, Moritz Sievers et al.
Clinical Infectious Diseases, Published: 26 December 2017
Artemisinin-based combination therapy (ACT) has made a major contribution to reducing the global malaria burden, but its role as first-line treatment is being eroded by the development of resistance. A priority is the development of new therapies with novel modes of action. Such therapies are being referred to as nonartemisinin-based combination therapies (NACTs). This is the first report of the use of the combination fosmidomycin–piperaquine. The combination appeared to have high efficacy and be safe and well tolerated despite observed transient changes in electrocardiogram with prolongation of the QT interval.